Table 2. Univariate association between individual parameters and survival.

Clinical and demographic markers		Genetic markers		Protein markers
					P-value per subcellular localisation
Parameters	P-value	Parameters	P-value	Parameters	Membranous	Cytoplasmic	Granular	Nuclear
Age	0.49
R0 vs R1/R2	0.057	EGFR FISH		EGFR	0.63	0.10 (0.099a)	—	0
Adenocarcinoma vs all other	0.54	No gain vs other	0.15	HER2	1	0.33	—	—
BAC vs all other	0.43	High polysomy vs other	0.13	pAKT.473	—	0.22	—	0.62
Squamous cell vs all other	0.42	Amplification vs other	0.72	pAKT.309	0.53	1	—	0.95
Large cell carcinoma vs all other	0.9			PTEN	—	0.63	—	0.69
Smoking (non vs current vs Former)	0.79	EGFR mutation		pERK	—	0.36	0.011	0.39
Stage (I vs II vs III)	0.04	WT vs other	0.15	pSTAT3	0.97	0.50	—	0.056 (0.11b)
Stage (I vs II/III)	0.015 (0.03c)	SNP vs other	0.70	pSTAT5	0.76	0.31	—	0.33
Pre-operative CT vs not	0.45	Mutant vs other	0.33	E-cadherin	0.32	0.031	—	—
Post-operative CT vs not	0.5			Vimentin	0.29	0.80	—	0.45
Post-operative RT vs not	0.15	KRAS mutation		HIF-1α	—	—	—	0.55
Pre-operative chemo-radiation vs not	0.031d	WT vs other	0.08	pCMET.1003	0.8	0.11	—	—
Other diseases vs not	0.37	SNP vs other	0.84	pCMET.1349	—	0.49	—	0.69
		Mutant vs other	0.08	pCMET.1230	0.88	0.90	—	0.68
				pCMET.1365	0.55	0.87	—	0.86

Abbreviations: CT=chemotherapy; EGFR=epidermal growth factor receptor; FISH=fluorescent in situ hybridization; R0, R1, R2=resection1, 2, 3; RT=radiotherapy; SNP=single nucleotide polymorphism; WT=wild type.

^aEGFR C: P=0.10 for 0–100 vs 160–300; P=0.20 after adjustment for new division in data.

^bpSTAT3 N: P=0.056 for 0–200 vs 210+; P=0.11 after adjusting P-value.

^cP=0.03 after adjustment for tests leading to re-grouping.

^dOnly three patients received pre-operative chemo-radiation; thus this parameter will not be considered in any other analyses.